Oragenics
OGEN
25 hedge funds and large institutions have $2.48M invested in Oragenics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 25 → 25 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
75% less capital invested
Capital invested by funds: $9.98M → $2.48M (-$7.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$9.35K |
| 3 |
Renaissance Technologies
New York
|
+$7.59K |
| 4 |
Jane Street
New York
|
+$7.01K |
| 5 |
LA
LexAurum Advisors
Overland Park,
Kansas
|
+$6.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9K |
| 2 |
Millennium Management
New York
|
-$7.01K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.84K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$3K |
| 5 |
BlackRock
New York
|
-$584 |
OGEN Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2022, worth a combined $2.48M — down 75% from $9.98M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OGEN positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $11.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $9K sold.
- 25 institutional investors held Oragenics (OGEN) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $2.48M of Oragenics stock for Q3 2022, down 75% quarter-over-quarter.
- 4 funds opened new Oragenics positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest Oragenics buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $11.7K added.
- The largest Oragenics seller in Q3 2022 was Susquehanna International Group, an estimated $9K sold.
Based on aggregated 13F filings for Q3 2022.